Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 4/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.37 |
| ▸ | FDPS | P14324 | 2/20 | 0.37 |
| ▸ | CTSK | P43235 | 2/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.36 |
| ▸ | PRMT6 | Q96LA8 | 4/20 | 0.34 |
| ▸ | KDR | P35968 | 4/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | CCNC | P24863 | 1/20 | 0.32 |
| ▸ | CDK8 | P49336 | 1/20 | 0.32 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25937496 | 0.86 | ERCC1 (0.38) | FDPSPRMT6CDK8 | |
| SCHEMBL24137805 | 0.81 | HTR7 (0.60) | HTR7ADRA1DHTR2CADRA1AADRA1B | |
| SCHEMBL24137806 | 0.69 | METAP2 (0.54) | KDR | |
| SCHEMBL24137867 | 0.67 | HTR7 (0.47) | HTR7ADRA1DHTR2CADRA1AADRA1B | |
| SCHEMBL25937910 | 0.66 | HTR7 (0.51) | HTR7ADRA1DHTR2CADRA1AADRA1B | |
| SCHEMBL24137550 | 0.65 | HTR7 (0.50) | HTR7ADRA1DHTR2CADRA1AADRA1B | |
| SCHEMBL27405411 | 0.65 | FDPS (0.60) | HTR7FDPSFLT3 | |
| SCHEMBL24137863 | 0.63 | CDK7 (0.46) | HTR7ADRA1DHTR2CADRA1AADRA1B | |
| SCHEMBL14160418 | 0.62 | MAPT (0.45) | — | |
| Lithium SCHEMBL5199989 | 0.62 | TDP1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234935-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234935-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | PACSIN2, MAP3K20, PHKG1 | HTR7 2493/4885ADRA1D 1291/4885HTR2C 2244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.